Easy hold and moon._老虎社区_美港股上老虎

Qaal
2021-05-04

Easy hold and moon.

After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading

(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares

After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":106287639,"tweetId":"106287639","gmtCreate":1620124650321,"gmtModify":1634207645089,"author":{"id":3577432645863048,"idStr":"3577432645863048","authorId":3577432645863048,"authorIdStr":"3577432645863048","name":"Qaal","avatar":"https://static.tigerbbs.com/0ebae6fa58e32daca8a545858cb2b589","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Easy hold and moon.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Easy hold and moon.&nbsp;</p></body></html>","text":"Easy hold and moon.","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/106287639","repostId":1157490418,"repostType":4,"repost":{"id":"1157490418","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620120727,"share":"https://www.laohu8.com/m/news/1157490418?lang=&edition=full","pubTime":"2021-05-04 17:32","market":"us","language":"en","title":"After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1157490418","media":"Tiger Newspress","summary":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares ","content":"<p style=\"text-align:left;\">(May 4)&nbsp;After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p>Shares of&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><b>So what</b></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><b>Now what</b></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter surging nearly 24% yesterday, OCGN dipped 4% in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-04 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p style=\"text-align:left;\">(May 4)&nbsp;After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.</p><p><img src=\"https://static.tigerbbs.com/231cd8867b2a322ce48be7afd711946c\" tg-width=\"633\" tg-height=\"479\" referrerpolicy=\"no-referrer\"><b>What happened</b></p><p>Shares of&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.</p><p><b>So what</b></p><p>Researchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.</p><p>\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"</p><p><b>Now what</b></p><p>Musunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157490418","content_text":"(May 4) After surging nearly 24% yesterday, OCGN dipped 4% in premarket trading.What happenedShares of Ocugen(NASDAQ:OCGN)surged 23.8% on Monday after thebiotechnologycompany released promising data from a study of Covaxin, the COVID-19 vaccine candidate it hopes to bring to the U.S. market.So whatResearchers at the Indian Council of Medical Research (ICMR) - National Institute of Virology believe Covaxin could protect against multiple coronavirus strains. Covaxin appeared to be effective against a variant from Brazil known as B.1.128.2. A previous study indicated that Covaxin could also protect against variants from the U.K. and India.\"Covaxin continues to show strong results in all the studies conducted to date,\" Ocugen co-founder and CEO Dr. Shankar Musunuri said in a press release. \"We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.\"Now whatMusunuri said Ocugen submitted a comprehensive drug master file to the U.S. Food and Drug Administration (FDA). The company is also preparing its application for an Emergency Use Authorization. Ocugen's agreement with its drug development partner, India-based Bharat Biotech, gives it a 45% share of any profits from the sale of Covaxin in the U.S., should it gain regulatory authorization.","news_type":1},"isVote":1,"tweetType":1,"viewCount":296,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}